"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B1,US 11583510 B1,172-999-034-203-118,2023-02-21,2023,US 202217666205 A,2022-02-07,US 202217666205 A,2022-02-07,Methods of administering gamma hydroxybutyrate formulations after a high-fat meal,Provided herein are methods of administering a once-nightly dosage of gamma-hydroxybutyrate after a high-fat meal.,FLAMEL IRELAND LTD,GRASSOT JULIEN;;MONTEITH DAVID;;GUILLARD HERVÉ;;MÉGRET CLAIRE;;DUBUISSON JEAN-FRANÇOIS,FLAMEL IRELAND LIMITED (2022-02-10),https://lens.org/172-999-034-203-118,Granted Patent,yes,929,6,1,1,0,A61K31/22;;A61P25/20;;A61K31/19;;A61K9/1676;;A61K9/5015;;A61K9/5026;;A61K9/5042;;A61K9/5078;;A61K9/5084;;A61K31/19;;A61K31/22;;A61K9/1676;;A61K9/5015;;A61P25/20;;A61K9/5042;;A61K9/5078;;A61K9/5084;;A61K9/5026,A61K31/19;;A61K9/16;;A61K9/50;;A61K31/22;;A61P25/20,,330,195,029-188-397-744-788;;072-092-992-312-755;;032-401-277-101-68X;;102-899-202-637-947;;098-921-526-264-417;;029-927-446-252-293;;107-803-152-503-328;;012-715-646-097-951;;139-898-841-231-714;;002-133-868-099-167;;082-516-623-800-461;;004-607-295-264-405;;003-670-671-253-618;;088-357-409-485-15X;;070-294-915-223-890;;011-939-910-538-16X;;100-322-709-101-560;;002-456-281-571-430;;010-682-458-523-318;;011-028-817-022-102;;041-562-305-799-872;;021-687-546-528-102;;003-903-956-202-86X;;087-943-082-376-60X;;070-781-218-543-66X;;057-604-658-890-296;;074-976-826-866-732;;015-290-985-099-538;;009-777-832-091-241;;007-173-895-633-271;;020-085-704-761-512;;104-164-856-886-905;;126-920-528-243-192;;018-012-288-721-765;;142-814-723-360-651;;142-814-723-360-651;;041-705-003-211-979;;046-368-296-007-863;;018-750-113-533-732;;140-135-460-870-387;;025-153-450-497-830;;045-566-373-797-573;;031-425-175-318-845;;027-444-799-578-724;;024-011-296-277-222;;004-428-730-717-330;;078-557-772-461-105;;041-707-954-761-959;;078-557-772-461-105;;087-258-840-842-425;;087-258-840-842-425;;076-552-368-130-78X;;079-676-865-061-504;;018-051-671-082-718;;089-104-576-317-883;;039-686-559-872-905;;014-048-669-449-514;;021-012-980-011-063;;088-837-947-994-464;;088-522-272-593-147;;039-091-327-430-806;;025-328-216-671-214;;100-431-235-487-547;;012-329-713-645-394;;076-892-282-478-970;;082-966-392-384-656;;049-897-594-177-433;;050-512-670-891-58X;;038-302-097-279-397;;149-981-625-199-350;;071-140-530-936-632;;015-234-856-714-307;;006-802-868-682-29X;;039-546-829-720-078;;055-637-635-577-983;;033-342-571-041-525;;021-846-723-963-953;;042-543-553-347-608;;099-425-313-501-806;;016-420-804-774-83X;;006-559-685-122-655;;125-702-998-664-408;;021-408-061-057-66X;;003-326-043-532-912;;006-315-038-449-896;;000-158-606-157-855;;000-397-376-273-399;;026-779-458-996-264;;099-084-439-220-388;;022-161-120-147-089;;089-025-115-631-911;;022-498-476-274-832;;175-760-637-920-073;;069-326-336-965-230;;036-257-273-433-136;;114-802-557-100-411;;121-178-758-769-047;;116-722-928-405-402;;124-875-834-903-459;;019-749-312-714-235;;004-006-455-390-942;;023-137-217-763-01X;;054-769-926-717-163;;012-733-712-942-922;;054-639-161-756-834;;045-816-277-025-820;;033-971-442-961-757;;010-002-135-609-166;;092-791-584-905-760;;012-922-935-375-243;;011-455-284-981-998;;058-102-534-979-295;;024-272-763-359-32X;;103-944-029-244-889;;003-974-588-505-653;;045-705-371-914-278;;005-743-877-740-38X;;061-699-838-737-669;;012-193-959-116-708;;010-923-926-694-72X;;031-263-913-335-411;;028-166-057-824-390;;145-653-484-736-088;;049-587-247-653-200;;008-884-065-882-911;;077-472-874-960-918;;083-098-800-297-922;;189-752-100-048-834;;043-727-834-695-425;;046-413-156-119-935;;172-372-589-987-05X;;002-209-609-529-386;;025-901-684-956-56X;;098-242-263-277-974;;043-760-241-736-994;;000-571-340-663-935;;015-727-310-665-481;;051-240-227-350-906;;065-910-111-913-752;;070-696-832-625-626;;095-180-557-299-845;;051-960-555-783-976;;081-765-993-885-23X;;064-220-053-202-690;;008-817-198-177-415;;105-650-780-806-12X;;055-156-128-870-846;;025-215-194-444-211;;065-307-604-175-771;;051-213-157-572-605;;063-404-351-886-496;;065-879-966-079-14X;;114-626-463-876-50X;;026-426-684-712-510;;109-074-384-469-937;;111-277-949-911-481;;037-121-151-148-672;;140-712-435-270-707;;064-998-466-553-357;;050-950-227-123-64X;;010-823-624-643-865;;057-219-328-325-605;;053-256-963-841-972;;001-839-669-883-31X;;062-952-206-640-917;;108-821-551-115-870;;046-793-273-956-430;;115-458-465-503-826;;083-042-335-037-531;;018-268-715-232-114;;080-496-076-280-55X;;006-942-348-871-366;;126-846-188-561-49X;;018-519-325-154-070;;133-738-947-965-336;;054-550-333-238-566;;005-742-584-546-802;;031-624-652-745-244;;048-661-321-942-876;;067-954-938-579-884;;010-896-739-614-543;;009-147-997-551-940;;085-355-647-680-219;;055-113-427-061-977;;038-143-822-189-111;;026-045-867-508-724;;004-132-848-932-586;;171-520-562-358-558;;014-102-610-862-536;;118-444-399-679-429;;021-950-272-011-792;;044-485-392-182-215;;056-785-398-853-921;;026-426-684-712-510;;035-116-966-994-803,10.1074/jbc.273.44.28959;;9786900;;27677382;;pmc5039898;;10.1186/s13063-016-1593-9;;28036099;;10.1111/fcp.12264;;11515679;;10.1007/s003840100299;;10.1016/j.ijpharm.2004.07.050;;15707739;;10.1002/med.21382;;26739481;;10.1093/sleep/27.7.1327;;15586785;;4124818;;192353;;10.1093/sleep/4.1.105;;7232968;;3704454;;10.1093/sleep/9.1.285;;10.1016/s0149-7634(89)80053-3;;2691926;;10.2147/tcrm.s119888;;27920540;;pmc5125720;;10.14740/jocmr2569w;;pmc4894018;;27298657;;10.1111/j.1553-2712.2002.tb02154.x;;10.1197/aemj.9.7.730;;12093716;;16105269;;10.1093/jat/29.5.398;;10.1520/jfs16174j;;10.1300/j094v01n03_05;;169541;;10.1097/00006842-197507000-00008;;10.5812/ircmj.17(4)2015.16761;;26023332;;pmc4443396;;26757307;;10.1097/wnf.0000000000000119;;10.1093/sleep/30.12.1705;;18246980;;pmc2276123;;pmc2574616;;10.1208/s12248-008-9035-6;;18523892;;15722403;;10.1124/jpet.105.083253;;pmc3608444;;10.1124/jpet.112.202796;;23392755;;27867997;;10.21037/atm.2016.10.60;;pmc5104623;;9277127;;10.1124/dmd.107.014852;;17502341;;10.1124/jpet.106.105965;;16707723;;4164970;;10.1016/0013-4694(67)90064-8;;15964179;;10.1016/j.ejps.2005.05.002;;11466174;;18852348;;10.1001/archneur.65.10.1337;;10.1007/s11894-006-0046-0;;16888867;;10.1007/bf00265954;;8299669;;10.1007/bf00265954;;8299669;;10.2165/00023210-200620120-00004;;17140279;;32651734;;10.1007/s11910-020-01057-z;;10.1016/j.colsurfa.2015.01.027;;10.1124/jpet.106.113886;;17138862;;10.1111/j.1469-7793.1998.819bs.x;;9508842;;pmc2230813;;10.1016/0006-2952(66)90045-1;;4293055;;10.1016/0028-3908(66)90007-4;;27807903;;10.1111/jsr.12468;;28731350;;10.1021/acs.molpharmaceut.7b00252;;20868750;;10.1016/j.ejpb.2010.09.004;;19116896;;10.1002/art.24142;;10.1016/j.pain.2010.12.022;;21397402;;19116896;;10.1002/art.24142;;26716917;;10.1056/nejmra1500587;;26716917;;10.1056/nejmra1500587;;22711238;;10.1002/j.1875-9114.2012.01108.x;;10.1016/0924-977x(93)90038-n;;10.1097/00002826-199201001-00157;;1498849;;15901598;;10.1152/ajpcell.00112.2005;;25721685;;10.1016/j.ijpharm.2015.02.051;;22722059;;10.1093/jat/bks053;;5550840;;10.1093/bja/43.2.110;;5550841;;10.1093/bja/43.2.113;;pmc2257868;;16872565;;10.1093/jat/30.6.360;;4061802;;10.1111/j.1365-2044.1985.tb10552.x;;27568803;;pmc5070748;;10.5665/sleep.6220;;10.1097/00000542-196411000-00007;;14225980;;15568693;;7449723;;10.1016/j.sleep.2016.09.013;;28153208;;10.1037/a0031692;;pmc3886725;;23421353;;19653937;;10.1093/jat/33.6.332;;28443381;;10.1080/14656566.2017.1323877;;10.1007/s40261-013-0158-x;;24307430;;10.1111/jsr.12374;;26809504;;21760777;;10.1155/2011/783196;;pmc3132498;;28449891;;10.1016/j.sleep.2017.01.002;;28179647;;10.1038/nrdp.2016.100;;28034493;;10.1016/j.sleep.2016.11.010;;27665501;;10.1016/j.sleep.2016.05.011;;10.1016/j.sleep.2016.08.010;;27887886;;26773222;;10.1016/j.forsciint.2015.12.009;;10.1016/0301-0082(73)90014-2;;6843688;;10.1007/bf00649351;;10.1124/dmd.109.030775;;19952290;;pmc2835396;;8506453;;10.1093/sleep/16.3.216;;2406848;;10.1093/sleep/13.1.24;;10.1371/journal.pone.0169836;;28107375;;pmc5249232;;10.1016/0006-2944(77)90034-5;;869940;;27411439;;pmc5473290;;10.1111/pedi.12390;;725311;;10.1016/j.sleep.2015.10.005;;26847972;;pmc5007834;;27581664;;10.1186/s13049-016-0299-z;;26659543;;pmc4834605;;10.1111/bcp.12863;;17564408;;10.5664/jcsm.26368;;pmc5344488;;28424564;;10.2147/nss.s103467;;10.1097/jcp.0b013e31815a2542;;18004131;;10.1196/annals.1369.065;;17105953;;pmc5253292;;28164110;;10.21037/atm.2016.12.63;;27228647;;10.1002/9780470259832.ch19;;5690534;;10.1213/00000539-196807000-00027;;10.5664/jcsm.2048;;22893778;;pmc3407266;;10.1016/s1359-6446(01)01922-5;;11522519;;7381722;;10.1002/jps.2600690331;;11067777;;10.1006/rtph.2000.1421;;10.1007/s11920-017-0763-0;;28243864;;27549768;;10.1007/s11940-016-0429-y;;10.1055/s-0036-1588019;;27564079;;2713866;;10.1097/00002826-198902000-00004;;10.1111/j.1651-2227.1994.tb13113.x;;7919772;;10.1002/bdd.525;;17061294;;16941233;;10.1007/s10928-006-9029-x;;28449892;;10.1016/j.sleep.2016.04.004;;pmc3014247;;21206549;;10.5664/jcsm.27994;;pmc5114175;;10.1016/j.pneurobio.2015.12.002;;26721620;;10.1016/s0939-6411(96)00028-8;;27778193;;10.1007/s40120-016-0053-5;;pmc5130920;;12520629;;10.1177/0091270002239707;;14973300;;10.1177/0091270003262795;;10.1016/j.smrv.2011.09.001;;22055895;;10.1016/b978-0-12-374194-3.00037-8;;27744373;;10.1093/jat/bkw107;;15538955;;10.1093/jat/28.8.625;;7388696;;10.1017/s0317167100119304;;264152;;10.1016/j.ijpharm.2013.10.034;;24177314;;28490912;;pmc5414617;;10.2147/nss.s103462;;10.1017/cem.2017.10;;28460656;;pmc2631377;;10.1016/j.pharmthera.2008.10.003;;19010351;;pmc2792587;;10.1007/s00213-009-1589-1;;19543883;;10.1016/j.sleep.2019.11.179;;10.1520/jfs15152j;;11714141;;9779855;;10.1016/0006-3223(89)90047-4;;2765597;;9703591;;10.1093/sleep/21.5.507;;12734908;;3888969;;26909768;;10.1111/jsr.12386;;2669980;;10.1016/0006-3223(89)90048-6;;1985252;;10.1056/nejm199101243240416;;10.1093/sleep/13.6.479;;2281247;;10.1246/bcsj.39.776;;1596007;;10.1164/ajrccm/145.6.1378;;9647355;;10.1023/a:1011976615750;;7260659;;10.1111/j.1528-1157.1988.tb03732.x;;3391142;;4269968;;10.1007/bf00501479;;27257716;;6145018;;9383489;;10.1111/j.1553-2712.1997.tb03677.x;;27523905;;10.1111/jsr.12444;;10.1210/jcem-44-5-1014;;858775;;pmc2850459;;20300894;;10.1208/s12249-010-9406-z;;pmc2766839;;16974199;;10.1097/01.jcp.0000237944.57893.28;;28159098;;10.1016/j.jsmc.2016.10.001;;10.1007/s40263-019-00689-1;;pmc6982634;;31953791;;10.1007/s11940-015-0347-4;;25854650;;28139340;;10.1016/j.forsciint.2017.01.015;;9365423;;10.3109/15563659709001236;;10.1136/gut.12.7.544;;pmc1411855;;5559143;;10.1007/bf01071310;;4452943;;10.1097/00004311-196900710-00007;;5392628;;10.1016/j.tiv.2017.10.015;;29031482;;pmc5842807;;pmc2409176;;10.1080/03639040701377292;;17882730;;17140255;;10.1021/mp060037b;;10.1124/dmd.106.012369;;17108059;;17377745;;10.1007/s11095-006-9228-6;;pmc2751446;;10.1208/s12248-007-9001-8;;18446505;;10.1016/0006-2952(83)90411-2;;6626270;;9678808;;10.1046/j.1365-2036.1998.00337.x;;10.1016/j.sleep.2016.12.003;;28065686;;10.1016/s0140-6736(07)60237-2;;17292770;;28153207;;10.1016/j.sleep.2016.05.008;;10.1172/jci109985;;6777399;;pmc371618;;21148631;;10.1530/eje-10-0913;;26541241;;10.1111/jsr.12363;;28108192;;10.1016/j.prrv.2016.12.005;;10421978;;20215411;;10.1124/jpet.109.165381;;pmc2879942;;20461486;;10.1208/s12248-010-9197-x;;pmc2895455;;pmc1381393;;1389947;;10.1111/j.1365-2125.1992.tb04129.x;;8399519;;10.1016/0731-7085(93)80161-s;;10.1016/j.forsciint.2011.09.014;;22014974;;26518705;;10.5664/jcsm.5594;;pmc4773621;;26574184;;10.1111/jsr.12357;;15986420;;10.1002/mds.20605;;16267211;;16382538;;10.1212/01.wnl.0000188670.38576.bd;;10.2165/00002018-200427050-00002;;15061684;;pmc2751451;;10.1208/s12248-007-9006-3;;18446506;;10.1016/j.vaccine.2016.08.062;;27577558;;7803523;;10.1007/bf02191883;;8397726;;10.1038/npp.1993.45;;2571021;;1326902;;10.1111/j.1530-0277.1992.tb00658.x;;pmc3098358;;10.1007/s11325-009-0320-0;;20082240;;7814832;;10.1097/00004850-199409000-00011;;10.1007/s11940-015-0347-4;;25854650;;31504554;;10.1093/ijnp/pyz047;;pmc6822136,"Kothare et al, Pharmacotherapy of Narcolepsy, Harvard Medical School. (Year: 2010).;;Lin R.Y., et al., “Human Monocarboxylate Transporter 2 (MCT2) Is a High Affinity Pyruvate Transporter,” The Journal of Biological Chemistry, Oct. 30, 1998, vol. 273 (44), pp. 28959-28965.;;Lingford-Hughes A., et al., “Improving GHB Withdrawal with Baclofen: Study Protocol for a Feasibility Study for a Randomized Controlled Trial,” Trials, 2016, vol. 17, pp. 1-11.;;Linselle M., et al., “Can Drugs Induce or Aggravate Sleep Apneas? A Case Non Case Study in Vigibase the WHO Pharmacovigilance Database,” Fundamental & Clinical Pharmacology, 2017, vol. 31 (3), pp. 359-366.;;Lubrano E., et al., “Fibromyalgia in Patients with Irritable Bowel Syndrome. An Association with the Severity of the Intestinal Disorder,” International Journal of Colorectal Disease, 2001, vol. 16 (4), pp. 211-215.;;Luhn O., “Using Excipients in Powder Formulations,” Pharmaceutical Technology Europe, Retrieved from URL: https://www.pharmtech.com/view/using-excipients-powder-formulations, Jan. 7, 2011, vol. 23 (1), 2 pages.;;Lusina M., et al., “Stability Study of Losartan/hydrochlorothiazide Tablets,” International Journal of Pharmaceutics, 2005, vol. 291 (1-2), pp. 127-137.;;Mahore J.G., et al., “Ion Exchange Resins: Pharmaceutical Applications and Recent Advancement,” International Journal of Pharmaceutical Sciences Review and Research, Mar.-Apr. 2010, vol. 1 (2), pp. 8-13.;;Maitre M., et al., “Mechanisms for the Specific Properties of y-Hydroxybutyrate in Brain,” Medicinal Research Reviews, 2016, vol. 36, pp. 1-25.;;Mamelak M., et al., “A Pilot Study on the Effects of Sodium Oxybate on Sleep Architecture and Daytime Alertness in Narcolepsy,” Sleep, 2004, vol. 27 (7), pp. 1327-1334.;;Mamelak M., et al., “Sleep-Inducing Effects of Gammahydroxybutyrate,” The Lancet, Aug. 11, 1973, vol. 302 (7824), pp. 328-329.;;Mamelak M., et al., “The Effects of y-Hydroxybutyrate on Sleep,” Biological Psychiatry, 1977, vol. 12 (2), pp. 273-288.;;Mamelak M., et al., “Treatment of Narcolepsy and Sleep Apnea with Gammahydroxybutyrate: A Clinical and Polysomnographic Case Study,” Sleep, 1981, vol. 4 (1), pp. 105-111.;;Mamelak M., et al., “Treatment of Narcolepsy with y-Hydroxybutyrate. A Review of Clinical and Sleep Laboratory Findings,” Sleep, 1986, vol. 9 (1), pp. 285-289.;;Mamelak M., “Gamma-hydroxybutyrate: An Endogenous Regulator of Energy Metabolism,” Neuroscience and Biobehavioral Reviews, 1989, vol. 13 (4), pp. 187-198.;;Maresova P., et al., “Treatment Cost of Narcolepsy with Cataplexy in Central Europe,” Therapeutics and Clinical Risk Management, 2016, vol. 12, pp. 1709-1715.;;Markman Opinion, filed Sep. 14, 2012, In the Case of Jazz Pharmaceuticals, Inc., Plaintiff, v. Roxane Laboratories, Inc., Defendant (United States District Court for the District of New Jersey, Civil 10-6108 ES, 43 pages.;;Martin John., “Capsule Endoscopy: How Long Does it Take to Pass,” Pill Cam, https://www.topdoctors.eo.uk/medical-articles/capsule-endoscopy-how-long-does-it-take-to-pass, Oct. 5, 2019, 4 Pages.;;Martinez-Orozco F.J., et al., “Comorbidity of Narcolepsy Type 1 With Autoimmune Diseases and Other Immunopathological Disorders: A Case-Control Study,” Journal of Clinical Medicine Research, 2016, vol. 8 (7), pp. 495-505.;;Mason P.E., et al., “Gamma Hydroxybutyric Acid (GHB) Intoxication,” Academic Emergency Medicine, 2002, vol. 9 (7), pp. 730-739.;;Mazarr-Proo S., et al., “Distribution of GHB in Tissues and Fluids Following a Fatal Overdose,” Journal of Analytical Toxicology, 2005, vol. 29 (5), pp. 398-400.;;Medicines for Children, “Oral Rehydration Salts,” Leaflet information by Neonatal and Paediatric Pharmacists Group (NPPG), Retrieved from URL: https://www.medicinesforchildren.org.uk/oral-rehyd ration-salts, published Jul. 25, 2013, 3 pages.;;Mesmer, et al., “Determination of Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL) by HPLC/UV-VIS Spectrophotometry and HPLC/Thermospray Mass Spectrometry,” Journal of Forensic Sciences, 1998, vol. 43 (3), pp. 489-492.;;Moldofsky H., “A Chronobiologic Theory of Fibromyalgia,” Journal of Musculoskeletal Pain, 1993, vol. 1 (1), pp. 49-59.;;Moldofsky H., et al., “Muskuloskeletal Symptoms and Non-REM Sleep Disturbance in Patients with ‘Fibrositis Syndrome’ and Healthy Subjects,” Psychosomatic Medicine, Jul.-Aug. 1975, vol. 37 (4), pp. 341-351.;;Momenzadeh S., et al., “Evaluation of in Vivo Transfection Efficiency of Eudragit Coated Nanoparticles of Chitosan-DNA: A pH-sensitive System Prepared for Oral DNA Delivery,” Iran Red Crescent Med J, Apr. 2015, vol. 17, No. 4, DOI: 10.5812/ircmj.16761, 7 Pages.;;Moresco M., et al., “Pharmacogenetics and Treatment Response in Narcolepsy Type 1: Relevance of the Polymorphisms of the Drug Transporter Gene ABCB1.” Clinical Neuropharmacology, 2016, vol. 39 (1), pp. 18-23.;;Morgenthaler T.I., “Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin,” Sleep, 2007, vol. 30 (12), 16 pages.;;Morris M.E., et al., “Overview of the Proton-coupled MCT (SLC16A) Family of Transporters: Characterization, Function and Role in the Transport of the Drug of Abuse Y-Hydroxybutyric Acid,” The American Association of Pharmaceutical Scientists, 2008, vol. 10 (2), pp. 311-321.;;Morris M.E., et al., “Renal Clearance of y-Hydroxybutyric Acid in Rats: Increasing Renal Elimination as a Detoxification Strategy,” Journal of Pharmacology and Experimental Therapeutics, 2005, vol. 313 (3), pp. 1194-1202.;;Morrison, Robert T., et al., “Organic Chemistry”, Chapter 20: “Functional Derivatives of Carboxylic Acids,” 3rd Edition, 1973, pp. 658-700.;;Morrison R.T., et al., “Organic Chemistry,” 3rd Edition, 1973, pp. 672-677.;;Morse B.L., et al., “Effects of Monocarboxylate Transporter Inhibition on the Oral Toxicokinetics/Toxicodynamics of y Hydroxybutyrate and y-Butyrolactone,” The Journal of Pharmacology and Experimental Therapeutics, 2013, vol. 345, pp. 102-110.;;Nellore A., et al., “Narcolepsy and Influenza Vaccination—the Inappropriate Awakening of Immunity,” Annals of Translational Medicine, 2016, vol. 4 (29), pp. 1-6.;;Nema S., et al., “Excipients and Their Use in Injectable Products,” PDA Journal of Pharmaceutical Science and Technology, Jul.-Aug. 1997, vol. 51 (4), pp. 166-171.;;Neuman A., “GHB's Path to Legitimacy: An Administrative and Legislative History of Xyrem,” Harvard Law School, Class of 2005, Food and Drug Law, Winter Term 2004, Professor Peter Barton Hutt, Apr. 2004, pp. 1-39.;;Non Final Office Action for U.S. Appl. No. 16/223,940, dated Apr. 15, 2020, 22 pages.;;Non Final Office Action for U.S. Appl. No. 16/804,966, dated Dec. 10, 2021, 13 pages.;;Non Final Office Action for U.S. Appl. No. 17/484,916, dated Nov. 10, 2021, 34 pages.;;Non-Final Office Action for U.S. Appl. No. 17/322,299 dated Mar. 15, 2022, 37 pages.;;Non-Final Office Action for U.S. Appl. No. 15/655,924, dated May 3, 2018, 15 pages.;;Non-Final Office action for U.S. Appl. No. 16/281,235, dated Jan. 24, 2020, 13 pages.;;Non-Final Office Action for U.S. Appl. No. 16/419,516, dated Jul. 9, 2020, 11 pages.;;Non-Final Office Action for U.S. Appl. No. 16/420,321, dated Aug. 26, 2020, 21 pages.;;Non-Final Office Action for U.S. Appl. No. 16/431,219, dated Aug. 26, 2020, 14 pages.;;Non-Final Office Action for U.S. Appl. No. 16/527,633, dated Feb. 18, 2021, 21 pages.;;Non-Final Office Action for U.S. Appl. No. 16/987,510, dated Dec. 1, 2020, 11 pages.;;Non-Final Office Action for U.S. Appl. No. 16/987,515, dated Dec. 24, 2020, 19 pages.;;Non-Final Office Action for U.S. Appl. No. 17/322,299, dated Jul. 21, 2021, 18 pages.;;Notice of Allowance for Japanese Application No. 2019-503463, dated Feb. 28, 2020, 6 pages.;;Notice of Allowance for U.S. Appl. No. 15/655,924, dated Feb. 7, 2019, 8 pages.;;Wang Q., et al., “The Role of Monocarboxylate Transporter 2 and 4 in the Transport of y-Hydroxybutyric Acid in Mammalian Cells,” Drug Metabolism and Disposition, 2007, vol. 35 (8), pp. 1393-1399.;;Wang Q., et al., “Transport of y-Hydroxybutyrate in Rat Kidney Membrane Vesicles: Role of Monocarboxylate Transporters,” Journal of Pharmacology and Experimental Therapeutics, 2006, vol. 318 (2), pp. 751-761.;;World Health Organization, “Annex 7: Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability,” WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report, Retrieved from URL: http://apps.who.int/prequal/infogeneral/documents/TRS937/WHOTRS937_eng.pdf#page=359, 2006, pp. 347-390.;;World Health Organization (WHO), “Guidelines on Packaging for Pharmaceutical Products,” WHO Technical Report Series, Annexure 9, 2002, pp. 119-156.;;Xyrem: “Mean Oxybate Plasma Concentration in Healthy Volunteers,” retrieved from URL: https://www.xyremhcp.com/xyrem-pharmacokinetics-adults, downloaded in Jul. 2021, 10 Pages.;;Xyrem (Sodium Oxybate)., “Highlights of Prescribing Information and Full Prescribing Information,” Jazz Pharmaceuticals Inc, Apr. 2015, 31 pages.;;Yamada Y., et al., “Effect of Butyrolactone and Gamma-Hydroxybutyrate on the EEG and Sleep Cycle in Man,” Electroencephalography and Clinical Neurophysiology, 1967, vol. 22 (6), pp. 558-562.;;Zheng J., “Formulation and Analytical Development for Low-Dose Oral Drug Products,” John Wiley & Sons Inc, Hoboken, New Jersey, Table 4.1, 2009, 28 pages.;;Notice of Allowance for U.S. Appl. No. 15/655,924, dated Dec. 11, 2018, 6 pages.;;Notice of Allowance for U.S. Appl. No. 15/655,924, dated Nov. 13, 2018, 11 pages.;;Notice of Allowance for U.S. Appl. No. 16/281,235, dated May 1, 2020, 8 pages.;;Notice of Allowance for U.S. Appl. No. 16/281,235, dated Jun. 26, 2020, 8 pages.;;Notice of Allowance for U.S. Appl. No. 16/419,516, dated Mar. 10, 2021, 8 pages.;;Notice of Allowance for U.S. Appl. No. 16/419,616, dated Dec. 10, 2020, 8 pages.;;Notice of Allowance for U.S. Appl. No. 16/420,321, dated Dec. 15, 2020, 8 pages.;;Notice of Allowance for U.S. Appl. No. 16/527,633, dated Jun. 9, 2021, 11 pages.;;Notice of Allowance for U.S. Appl. No. 16/987,510, dated Jan. 13, 2021, 8 pages.;;Notification of Issue for U.S. Appl. No. 16/281,235, dated Aug. 11, 2020, filed May 29, 2000, 1 Page.;;Office Action for Argentina Patent Application No. 20170102053, dated Nov. 9, 2021, 5 Pages.;;Office Action for Japanese Patent Application No. 2020055505, dated Oct. 28, 2021, 11 Pages.;;Office Action for Canada Application No. 3,028,878, dated Feb. 18, 2020, 3 pages.;;Office Action for Canadian Patent Application No. 3084120, dated Aug. 26, 2021, 5 Pages.;;Office Action for Chinese Patent Application No. 201880082447.4, dated Oct. 12, 2021, 20 Pages.;;Office Action for European Patent Application No. 17742441.3, dated Mar. 11, 2022, 7 Pages.;;Office Action for Japanese Patent Application No. 2020-055505, dated Mar. 12, 2020, 9 Pages.;;Office Action for Japanese Patent Application No. 2020055505, dated Feb. 21, 2022, 11 Pages.;;Ohta K.M., et al., “Development of a Simple Method for the Preparation of a Silica Gel Based Controlled Delivery System With a High Drug Content,” European Journal of Pharmaceutical Sciences, 2005, vol. 26 (1), pp. 87-96.;;Okun M.S., et al., “GHB: An Important Pharmacologic and Clinical Update,” Journal of Pharmaceutical Sciences, 2001, vol. 4 (2), pp. 167-175.;;Ondo W.G., et al., “Sodium Oxybate for Excessive Daytime Sleepiness in Parkinson's Disease: An Open-Lable Polysomnographic Study,” Arch Neural, Oct. 2008, vol. 65 (10), pp. 1337-1340.;;Order, filed Sep. 14, 2012, in the case of Jazz Pharmaceuticals, Inc., Plaintiff, v. Roxane Laboratories, Inc., Defendant (United States District Court for the District of New Jersey, Civil 10-6108 ES).;;Outlaw W.M., et al., “Dyspepsia and its Overlap with Irritable Bowel Syndrome,” Current Gastroenterology Reports, 2006, vol. 8 (4), pp. 266-272.;;Palatini P., et al., “Dose Dependent Absorption and Elimination of Gamma-Hydroxybutyric Acid in Healthy Volunteers,” European Journal of Clinical Pharmacology, 1993, vol. 45 (4), pp. 353-356.;;Palatini P., et al., “Dose-Dependent Absorption and Elimination of Gamma-Hydroxybutyric Acid in Healthy Volunteers,” European Journal of Clinical Pharmacology, 1993, vol. 45, pp. 353-356.;;Pardi D., et al., “y-Hydroxybutyrate/Sodium Oxybate; Neurobiology, and Impact on Sleep and Wakefulness,” Central Nervous System Drugs, 2006, vol. 20 (12), pp. 993-1018.;;Parmar A., et al., “Clinical Characteristics of Cataplectic Attacks in Type 1 Narcolepsy,” Current Neurology and Neuroscience Reports, 2020, vol. 20 (38), 9 pages.;;Patil P., et al., “A Review on Ionotropic Gelation Method: Novel Approach for Controlled Gastroretentive Gelispheres,” International Journal of Pharmacy and Pharmaceutical Sciences, 2012, vol. 4, Suppl 4, pp. 27-32.;;“Pharma Excipients,” Eudragit® L 100-55, Description, Additional Information, Mar. 2022, 2 pages, Retrieved from the internet URL: https://www.pharmaexcipients.com/product/eudragit-l-100-55/.;;“Phospholine Iodide,” Physicians Desk Reference, 50th Edition, 1996, p. 2784.;;Puguan J.M.C., et al., “Diffusion Characteristics of Different Molecular Weight Solutes in Ca-Alginate Gel Beads,” Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2015, vol. 469, pp. 158-165.;;Raybon J.J., et al., “Pharmacokinetics and Pharmacodynamics of y-Hydroxybutyric Acid during Tolerance in Rats: Effects on Extracellular Dopamine,” The Journal of Pharmacology and Experimental Therapeutics, 2007, vol. 320 (3), pp. 1252-1260.;;Raymond C.R., “Polymethacrylates,” Handbook of Pharmaceutical Excipients, Fifth Edition, Pharmaceutical Press, London, 2006, pp. 553-560.;;Ritzhaupt A., et al., “The Characterization of Butyrate Transport across Pig and Human Colonic Luminal Membrane,” Journal of Physiology, 1998, vol. 507 (3), pp. 819-830.;;Roth R.H., et al., “y-Butyrolactone and y-Hydroxybutyric Acid—I, Distribution and Metabolism,” Biochemical Pharmacology, 1966, vol. 15 (9), pp. 1333-1348.;;Roth R.H., et al., “y-Butyrolactone and y-Hydroxybutyric Acid—II, The Pharmacologically Active Form,” International Journal of Neuropharmacology, 1966, vol. 5 (6), pp. 421-428.;;Roth T., et al., “Effect of Sodium Oxybate on Disrupted Night Time Sleep in Patients with Narcolepsy,” Journal of Sleep Research, 2017, vol. 26, pp. 407-414.;;Roxane Laboratories Inc., “Answer, Affirmative Defenses and Counterclaims to Plaintiff's Complaint,” dated Jun. 1, 2011, 12 pages.;;Roxane Laboratories Inc.,“Answer, Affirmative Defenses and Counterclaims to Plaintiff's Complaint,” dated Mar. 9, 2011, 13 pages.;;Roxane Laboratories Inc., “Answer, Affirmative Defenses and Counterclaims to Plaintiff's Complaint,” dated Nov. 9, 2012, 18 pages.;;Roxane Laboratories Inc., “Answer, Affirmative Defenses and Counterclaims to Plaintiff's Complaint,” dated Dec. 29, 2010, 21 pages.;;Roxane Laboratories Inc., “Answer and Affirmative Defenses to Plaintiff's Complaint,” dated Jan. 4, 2013, 8 pages.;;Roxane Laboratories Inc., “Intitial Invalidity and Noninfringement Contentions Pursuant to Local Patent Rule 3.6,” dated Apr. 14, 2011, 23 pages.;;Rubbens J., et al., “Gastric and Duodenal Ethanol Concentrations after Intake of Alcoholic Beverages in Postprandial Conditions,” Molecular Pharmaceutics, 2017, vol. 14 (12), pp. 4202-4208.;;Rujivipat., et al., “Improved Drug Delivery to the Lower Intestinal Tract with Tablets Compression-Coated with Enteric/Nonenteric Polymer Powder Blends,” European Journal of Pharmaceutics and Biopharmaceutics, 2010, vol. 76, pp. 486-492.;;Russell I.J., et al., “Sodium Oxybate Relieves Pain and Improves Function in Fibromyalgia Syndrome,” Arthritis & Rheumatism, Jan. 2009, vol. 60 (1), pp. 299-309.;;Russell J., et al., “Sodium Oxybate Reduces Pain, Fatigue, and Sleep Disturbance and Improves Functionality in Fibromyalgia: Results from a 14-week, Randomized, Double-Blind, Placebo-Controlled Study,” Pain, 2011, vol. 152 (5), pp. 1007-1017.;;Russell J., et al., “Sodium Oxybate Relieves Pain and Improves Function in Fibromyalgia Syndrome. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial,” Arthritis & Rheumatism, 2009, vol. 60 (1), pp. 299-309.;;Scammell T.E., “Narcolepsy,” The New England Journal of Medicine, Dec. 31, 2015, vol. 373, No. 27, pp. 2654-2662.;;Scammell T.E., “Narcolepsy,” The New England Journal of Medicine, vol. 373 (27), Dec. 31, 2015, 9 pages.;;Non-Final Office Action for U.S. Appl. No. 17/497,366 dated Apr. 27, 2022, 24 pages.;;Pai M.P., et al., “Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese Adults,” Pharmacotherapy, Sep. 2012, vol. 32, No. 9, pp. 856-868.;;Gessa G.L., et al., “Gamma-Hydroxybutyric acid (GHB) for Treatment of Ethanol Dependence,” European Neuropsychopharmacology, 1993, vol. 3 (3), pp. 224-225.;;Gessa G.L., et al., “Gamma-Hydroxybutyric Acid in the Treatment of Alcohol Dependence,” Clinical Neuropharmacology, 1992, vol. 15, Suppl. 1, Pt. A, pp. 303A-304A.;;Gill R.K., et al., “Expression and Membrane Localization of MCT Isoforms along the Length of the Human Intestine,” American Journal of Physiology—Cell Physiology, 2005, vol. 289, pp. C846-C852.;;Goyanes A., et al., “Gastrointestinal Release Behaviour of Modified-Release Drug Products: Dynamic Dissolution Testing of Mesalazine Formulations,” International Journal of Pharmaceutics, 2015, vol. 484, No. 1-2, pp. 103-108, Retrieved from the Internet: URL: https://discovery.ucl.ac.uk/id/eprint/1462647/3/Basit.1462647_5-ASA.pdf.;;Grenier V., et al., “Enzymatic Assay for GHB Determination in Forensic Matrices,” Journal of Analytical Toxicology, 2012, vol. 36, pp. 523-528.;;Grove-White I.G., et al., “Critical Flicker Frequency after Small Doses of Methohexitone, Diazepam and Sodium 4-Hydroxybutyrate,” British Journal of Anaesthesia, Feb. 1971, vol. 43 (2), pp. 110-112.;;Grove-White I.G., et al., “Effect of Methohexitone, Diazepam and Sodium 4-Hydroxybutyrate on Short-Term Memory,” British Journal of Anaesthesia, Feb. 1971, vol. 43 (2), pp. 113-116.;;Haller C., et al., “GHB Urine Concentrations After Single-Dose Administrationin Humans,” Journal of Analytical Toxicology, 2006, vol. 30, pp. 360-364.;;Haque T., et al., “Model Dependent and Independent Approaches to Compare in Vito Release Profiles From Ethylcellulose and Eudragit L100 Based Matrix Tablets,” Dhaka University Journal of Pharmaceutical Sciences, 2009, vol. 8 (1), pp. 89-98.;;Hasenbos M.A.W.M., et al., “Anaesthesia for Bullectomy, A Technique With Spontaneous Ventilation and Extradural Blockade,” Anaesthesia, 1985, vol. 40 (10), pp. 977-980.;;Heide A.V.D., et al., “Core Body and Skin Temperature in Type 1 Narcolepsy in Daily Life; Effects of Sodium Oxybate and Prediction of Sleep Attacks,” Sleep, 2016, vol. 39 (11), pp. 1941-1949.;;Helrich M., et al., “Correlation of Blood Levels of 4-Hydroxybutyrate with State of Consciousness,” Anesthesiology, 1964, vol. 25 (6), pp. 771-775.;;Hennessy S.A., et al., “The Reactivity of Gamma-Hydroxybutyric acid (GHB) and Gamma-Butyrolactone (GBL) in Alcoholic Solutions,” Journal of Forensic Sciences, 2004, vol. 49 (6), pp. 1-10.;;“Hib-Imune,” Physicians Desk Reference, 41st Edition, 1987, pp. 1095-1096.;;“HibVAX,” Physicians Desk Reference, 41st Edition, 1987, p. 870.;;Hoes M.J.A.J.M., et al., “Gamma-Hydroxybutyric Acid (*) as Hypnotic, Clinical and Pharmacokinetic Evaluation of Gamma Hydroxybutyric Acid as Hypnotic in Man,” L'Encephale: Revue de psychiatry clinique biologique et therapeutique, 1980, vol. 6 (1), pp. 93-99.;;International Preliminary Report on Patentability for International Application No. PCT/EP2017/068552, dated Jan. 31, 2019, 9 pages.;;International Search Report and Written Opinion for International Application No. PCT/B2018/060278, dated Apr. 15, 2019, 8 pages.;;International Search Report and Written Opinion for International Application No. PCT/EP2017/068552, dated Sep. 15, 2017, 10 pages.;;International Search Report and Written Opinion for International Application No. PCT/IB2020/051726, dated May 18, 2020, 13 pages.;;Jazz Pharmaceuticals, Inc., “XYREM® (sodium oxybate) oral solution Prescribing Information,” XYREM® US Package Insert available at http://pp.jazzpliamia.com/pi/xyem.en.USPI.pdf (downloaded Sep. 12, 2017, 32 pages.;;Jazz Pharmaceuticals., “Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness,” Retrieved from URL: https://investor.jazzpharma.com/node/16206/pdf, Mar. 26, 2019, 2 pages.;;Jefferies, Flamel Technologies SA publication, https://www.jefferies.com/CMSFiles/Jefferies.com/files/Flamel.pdf, May 1, 2015, 1 Page.;;Jennum P., et al., “Morbidity of Childhood Onset Narcolepsy: A Controlled National Study,” Sleep Medicine, 2017, vol. 29, pp. 13-17.;;Jha M.K., “Modified Release Formulations to Achieve the Quality Target Product Profile (QTPP),” IJPSR, 2012, vol. 3, No. 8, pp. 2376-2386.;;Johnson M.W., et al., “Comparative Abuse Liability of GHB and Ethanol in Humans,” Experimental and Clinical Psychopharmacology, 2013, vol. 21 (2), pp. 112-123.;;Jones A.W., et al., “Concentration-Time Profiles of Gamma-Hydroxybutyrate in Blood After Recreational Doses are Best Described by Zero-Order Rather Than First-Order Kinetics,” Journal of Analytical Toxicology, 2009, vol. 33, pp. 332-335.;;Kallweit U., et al., “Pharmacological Management of Narcolepsy with and without Cataplexy,” Expert Opinionon Pharmacotherapy, 2017, vol. 18 (8) pp. 809-817.;;Keating G.M., “Sodium Oxybate: A Review of Its Use in Alcohol Withdrawal Syndrome and in the Maintenance of Abstinence in Alcohol Dependence,” Clinical Drug Investigation, 2014, vol. 34, pp. 63-80.;;Khatami R., et al., “The European Narcolepsy Network (EU-NN) database,” Journal of Sleep Research, 2016, vol. 25, pp. 356-364.;;Khediri F., et al., “Efficacy of Diosmectite (Smecta) in the Treatment of Acute Watery Diarrhea in Adults: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study,” Hindawi Publishing Corporation, Gastroenterology Research and Practice, 2011, vol. 2011, Article ID 783196, 9 pages.;;Kollb-Sielecka M., et al., “The European Medicines Agency Review of Pitolisant for Treatment of Narcolepsy: Summary of the Scientific Assessment by the Committee for Medicinal Products for Human Use,” Sleep Medicine, 2017, vol. 33, pp. 125-129.;;Kornum B.R., et al., “Narcolepsy,” Nature Reviews/Disease Primers, Feb. 9, 2017, vol. 3, pp. 1-19.;;Kovalska P., et al., “Higher Body Mass Index in Narcolepsy with Cataplexy: Lifelong Experience”, Sleep Medicine, 2017, vol. 32, 1 page.;;Kovalska P., et al., “Narcolepsy with Cataplexy in Patients Aged Over 60 years: A Case-Control Study,” Sleep Medicine, 2016, vol. 26, pp. 79-84.;;Krahn L.E., “Understanding the Needs of Older Patients with Narcolepsy,” Sleep Medicine, 2016, vol. 26, 3 pages.;;Kristoffersen L., et al., “Determination of Safety Margins for Whole Blood Concentrations of Alcohol and Nineteen Drugs in Driving Under the Influence Cases,” Forensic Science International, 2016, vol. 259, pp. 119-126.;;Laborit H., “Gamma-Hydroxybutyrate, Succinic Semialdehyde and Sleep,” Laboratoire d'Eutonologie, 1973, pp. 257-274.;;Ladinsky H., et al., “Mode of Action of Gamma-Butyrolactone on the Central Cholinergic System,” Naunyn-Schmiedeberg's, Arch Pharmacol, 1983, vol. 322 (1), pp. 42-48.;;Lam W.K., et al., “Monocarboxylate Transporter-Mediated Transport of y-Hydroxybutyric Acid in Human Intestinal Caco-2 Cells,” Drug Metabolism and Disposition, 2010, vol. 38 (3), pp. 441-447.;;Lammers G.J., et al., “Gamma-Hydroxybutyrate and Narcolepsy: A Double-Blind Placebo-Controlled Study,” Sleep, 1993, vol. 16 (3), pp. 216-220.;;Lapierre, et al., “The Effect of Gamma-Hydroxybutyrate: A Double-Blind Study of Normal Subjects,” Sleep Research, 1988, vol. 17 (99), 6 pages.;;Lapierre O., et al., “The Effect of Gamma-Hydroxybutyrate on Nocturnal and Diurnal Sleep of Normal Subjects: Further Considerations on REM Sleep-Triggering Mechanisms,” Sleep, 1990, vol. 13 (1), pp. 24-30.;;Lecendreux M., et al., “Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells,” PLoS ONE, Jan. 20, 2017, pp. 1-14.;;Lee C.R., “Evidence for the Beta-Oxidation of Orally Administered 4-Hydroxybutyrate in Humans,” Biochemical Medicine, 1977, vol. 17 (3), pp. 284-291.;;Lernmark A., “Environmental Factors in the Etiology of Type 1 Diabetes, Eliac Disease and Narcolepsy,” Pediatric Diabetes, Jul. 2016, vol. 17 (22), pp. 65-72.;;Lettieri J., et al., “Improved Pharmacological Activity via Pro-Drug Modification: Comparative Pharmacokinetics of Sodium Gamma-hydroxybutyrate and Gamma-butyrolactone,” Research Communications in Chemical Pathology and Pharmacology, Oct. 1, 1978, vol. 22 (1), pp. 107-118.;;Leu-Semenescu., et al., “Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review,” Sleep Medicine, Jan. 2016, vol. 17, pp. 38-44.;;Liakoni E., et al., “Presentations to an Urban Emergency Department in Switzerland Due to Acute Y-hydroxybutyrate Toxicity,” Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2016, vol. 24 (107), pp. 1-9.;;Liechti M.E., et al., “Pharmacokinetics and Pharmacodynamics of y-Hydroxybutyrate in Healthy Subjects,” British Journal of Clinical Pharmacology, 2016, vol. 81, pp. 980-988.;;A Double-Blind, Placebo-Controlled Study Demonstrates Sodium Oxybate is Effective for the Treatment of Excessive Daytime Sleepiness in Narcolepsy, Xyrem International Study Group, Journal of Clinical Sleep Medicine, 2005, vol. 1 (4), pp. 391-397.;;Abad V.C., et al., “New Developments in the Management of Narcolepsy,” Nature and Science of Sleep, 2017, vol. 9, pp. 39-57.;;Abanades S., et al., “Relative Abuse Liability of y-Hydroxybutyric Acid, Flunitrazepam, and Ethanol in Club Drug Users,” Journal of Clinical Psychopharmacology, 2007, vol. 27 (6), pp. 625-638.;;Abanades S., et al., “y-Hydroxybutyrate (GHB) in Humans, Pharmacodynamics and Pharmacokinetics,” Annals New York Academy of Sciences, 2006, vol. 1074, pp. 559-576.;;“Activase,” Physicians Desk Reference, 50th Edition, 1996, pp. 312, 1058-1061.;;Ahmed S.M., et al., “Narcolepsy and Influenza Vaccination-Induced Autoimmunity,” Annals of Translational Medicine, 2017, vol. 5 (1), pp. 1-4.;;Ahmed S.M., et al., “The Safety of Adjuvanted Vaccines Revisited: Vaccine-Induced Narcolepsy,” The Israel Medical Association Journal, 2016, vol. 18, pp. 216-220.;;Akala E.O., “Effect of Packaging on Stability of Drugs and Drug Products,” Pharmaceutical Manufacturing Handbook: Regulations and Quality, 2008, pp. 641-686.;;Akifuddin S.K., et al., “Preparation, Characterization and In-Vitro Evaluation of Microcapsules for Controlled Release of Diltiazem Hydrochloride by Ionotropic Gelation Technique,” Journal of Applied Pharmaceutical Science, Apr. 2013, vol. 3 (4), pp. 35-42.;;Aldrette J.A., et al., “Does Magnesium Produce Anesthesia Evaluation of Its Effects on the Cardiovascular and Neurologic Systems,” Anesthesia and Analgesia, 1968, vol. 47 (4), pp. 428-433.;;Alshaikh M.K., et al., “Sodium Oxybate for Narcolepsy with Cataplexy: Systematic Review and Meta-Analysis,” Journal of Clinical Sleep Medicine, 2012, vol. 8 (4), pp. 451-458.;;“Amberlite IRN78 Resin, Nuclear Grade Strong Base Anion Resin,” The Dow Chemical Company, Product Data Sheet, Form No. 177-02230-0311, Rev 0, 3 pages.;;Anand V., et al., “Ion-Exchange Resins: Carrying Drug Delivery Forward,” Drug Discovery Today 2001, Sep. 17, 2001, vol. 6 (17), pp. 905-914.;;Anonymous, “The Engineering Toolbox,” Retrieved from internet URL: https://www.engineeringtoolbox.com/relative-humidity-production-processd_511.html, 2003, 3 pages.;;Arena C., et al., “Absorption of Sodium y-Hydroxybutyrate and Its Prodrug y-Butyrolactone: Relationship between In Vitro Transport and In Vivo Absorption,” Journal of Pharmaceutical Sciences, 1980, vol. 69 (3), pp. 356-358.;;Baldrick P., “Pharmaceutical Excipient Development: The Need for Preclinical Guidance,” Regulatory Toxicology and Pharmacology, Oct. 2000, vol. 32 (2), pp. 210-218.;;Barateau L., et al., “Hypersomnolence, Hypersomnia, and Mood Disorders,” Current Psychiatry Reports, 2017, vol. 19, pp. 1-11.;;Barateau L., et al., “Management of Narcolepsy,” Current Treatment Options in Neurology, 2016, vol. 18, pp. 1-13.;;Bayram A.K., et al., “Efficiency of a Combination of Pharmacological Treatment and Nondrug Interventions in Childhood Narcolepsy,” Neuropediatrics, 2016, vol. 47 (6), pp. 380-387.;;Bedard M.A., et al., “Nocturnal y-Hydroxybutyrate—Effect on Periodic Leg Movements and Sleep Organization of Narcoleptic Patients,” Clinical Neuropharmacology, Feb. 1989, vol. 12 (1), pp. 29-36.;;Berthier M., et al., “Possible Involvement of a Gamma-Hydroxybutyric Acid Receptor in Startle Disease,” Acta Paediatr, 1994, vol. 83, pp. 678-680.;;Bhattacharya I., et al., “Feasibility of D-Glucuronate to Enhance y-Hydroxybutyric Acid Metabolism During y-Hydroxybutyric Acid Toxicity: Pharmacokinetic and Pharmacodynamic Studies,” Biopharmaceutics & Drug Disposition, 2007, vol. 28, pp. 1-11.;;Bhattacharya I., et al., “Potential y-Hydroxybutyric acid (GHB) Drug Interactions Through Blood-Brain Barrier Transport Inhibition: A Pharmacokinetic Simulation-Based Evaluation,” Journal of Pharmacokinetics and Pharmacodynamics, 2006, vol. 33 (5), pp. 657-681.;;BioSpace: “Flamel Technologies Announces Positive Results of a Second Clinical Trial with Micropump® Sodium Oxybate,” BioSpace, Published on: Dec. 22, 2014, 6 Pages.;;Black J., et al., “Medical Comorbidity in Narcolepsy: Findings from the Burden of Narcolepsy Disease (BOND) Study,” Sleep Medicine, 2017, vol. 33, pp. 13-18.;;Black J., et al., “The Nightly Use of Sodium Oxybate Is Associated with a Reduction in Noctural Sleep Disruption: A Double-Blind, Placebo-Controlled Study in Patients with Narcolepsy,” Journal of Clinical Sleep Medicine, 2010, vol. 6 (6), pp. 596-602.;;Black S.W., et al., “Challenges in the Development of Therapeutics for Narcolepsy,” Prog Neurobiol., 2017, vol. 152, pp. 89-113.;;Bodmeier R., “Tableting of Coated Pellets,” European Journal of Pharmaceutics and Biopharmaceutics, 1997, vol. 43 (1), pp. 1-8.;;Bogan R., et al., “Evaluation of Quality of Life in Patients With Narcolepsy Treated with Sodium Oxybate: Use of the 36-Item Short-Form Health Survey in a Clinical Trial,” Neurology and Therapy, 2016, vol. 5, pp. 203-213.;;Borgen L., et al., “Xyrem (sodium oxybate): A Study of Dose Proportionality in Healthy Human Subjects,” Journal of Clinical Pharmacology, 2000, vol. 40, p. 1053.;;Borgen L.A., et al., “The Influence of Gender and Food on the Pharmacokinetics of Sodium Oxybate Oral Solution in Healthy Subjects,” Journal of Clinical Pharmacology, 2003, vol. 43, pp. 59-65.;;Borgen L.A., et al., “The Pharmacokinetics of Sodium Oxybate Oral Solution following Acute and Chronic Administration to Narcoleptic Patients,” Journal of Clinical Pharmacology, 2004, vol. 44, pp. 253 257.;;Boscolo-Berto R., et al., “Narcolepsy and Effectiveness of Gamma-Hydroxybutyrate (GHB): A Systematic Review and Meta-analysis of Randomized Controlled Trials,” Sleep Medicine Reviews, 2012, vol. 16, pp. 431-443.;;Bowker M.J., et al., “Preparation of Water-Soluble Compounds Through Salt Formulation,” Edited by Wermuth C.G., The Practice of Medicinal Chemistry, Academic Press, Third Edition, Chapter 37, 2008, pp. 749-766.;;Brailsford A.D., et al., “Increases in Serum Growth Hormone Concentrations Associated with GHB Administration,” Journal of Analytical Toxicology, 2017, vol. 41, pp. 54-59.;;Brenneisen R., et al., “Pharmacokinetics and Excretion of Gamma-Hydroxybutyrate (GHB) in Healthy Subjects,” Journal of Analytical Toxicology, 2004, vol. 28, pp. 625-630. et al.",ACTIVE
